vs
Apellis Pharmaceuticals, Inc.（APLS）与COHEN & STEERS, INC.（CNS）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是COHEN & STEERS, INC.的1.4倍（$199.9M vs $143.8M），COHEN & STEERS, INC.净利率更高（24.3% vs -29.5%，领先53.7%），COHEN & STEERS, INC.同比增速更快（2.9% vs -5.9%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-126.4M），过去两年COHEN & STEERS, INC.的营收复合增速更高（8.3% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
科恩斯蒂尔是一家美国投资管理企业，专注于通过房地产投资信托（REIT）开展不动产证券投资，同时布局优先证券相关的另类收益类投资业务，在全球不动产和另类收益投资领域拥有专业的运营经验。
APLS vs CNS — 直观对比
营收规模更大
APLS
是对方的1.4倍
$143.8M
营收增速更快
CNS
高出8.8%
-5.9%
净利率更高
CNS
高出53.7%
-29.5%
自由现金流更多
APLS
多$112.1M
$-126.4M
两年增速更快
CNS
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $143.8M |
| 净利润 | $-59.0M | $34.9M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 28.0% |
| 净利率 | -29.5% | 24.3% |
| 营收同比 | -5.9% | 2.9% |
| 净利润同比 | -62.2% | -23.9% |
| 每股收益（稀释后） | $-0.40 | $0.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSCNS
| Q4 25 | $199.9M | $143.8M | ||
| Q3 25 | $458.6M | $141.7M | ||
| Q2 25 | $178.5M | $136.1M | ||
| Q1 25 | $166.8M | $134.5M | ||
| Q4 24 | $212.5M | $139.8M | ||
| Q3 24 | $196.8M | $133.2M | ||
| Q2 24 | $199.7M | $121.7M | ||
| Q1 24 | $172.3M | $122.7M |
净利润APLSCNS
| Q4 25 | $-59.0M | $34.9M | ||
| Q3 25 | $215.7M | $41.7M | ||
| Q2 25 | $-42.2M | $36.8M | ||
| Q1 25 | $-92.2M | $39.8M | ||
| Q4 24 | $-36.4M | $45.8M | ||
| Q3 24 | $-57.4M | $39.7M | ||
| Q2 24 | $-37.7M | $31.8M | ||
| Q1 24 | $-66.4M | $34.0M |
营业利润率APLSCNS
| Q4 25 | -25.6% | 28.0% | ||
| Q3 25 | 48.7% | 34.5% | ||
| Q2 25 | -18.6% | 31.8% | ||
| Q1 25 | -50.0% | 33.6% | ||
| Q4 24 | -12.3% | 35.3% | ||
| Q3 24 | -24.0% | 33.7% | ||
| Q2 24 | -14.7% | 31.5% | ||
| Q1 24 | -36.0% | 32.8% |
净利率APLSCNS
| Q4 25 | -29.5% | 24.3% | ||
| Q3 25 | 47.0% | 29.4% | ||
| Q2 25 | -23.6% | 27.1% | ||
| Q1 25 | -55.3% | 29.6% | ||
| Q4 24 | -17.1% | 32.8% | ||
| Q3 24 | -29.2% | 29.8% | ||
| Q2 24 | -18.9% | 26.1% | ||
| Q1 24 | -38.5% | 27.7% |
每股收益（稀释后）APLSCNS
| Q4 25 | $-0.40 | $0.67 | ||
| Q3 25 | $1.67 | $0.81 | ||
| Q2 25 | $-0.33 | $0.72 | ||
| Q1 25 | $-0.74 | $0.77 | ||
| Q4 24 | $-0.30 | $0.89 | ||
| Q3 24 | $-0.46 | $0.77 | ||
| Q2 24 | $-0.30 | $0.63 | ||
| Q1 24 | $-0.54 | $0.68 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $145.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $562.0M |
| 总资产 | $1.1B | $876.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSCNS
| Q4 25 | $466.2M | $145.5M | ||
| Q3 25 | $479.2M | $98.1M | ||
| Q2 25 | $370.0M | $95.4M | ||
| Q1 25 | $358.4M | $65.2M | ||
| Q4 24 | $411.3M | $183.0M | ||
| Q3 24 | $396.9M | $106.5M | ||
| Q2 24 | $360.1M | $122.0M | ||
| Q1 24 | $325.9M | $99.5M |
总债务APLSCNS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSCNS
| Q4 25 | $370.1M | $562.0M | ||
| Q3 25 | $401.2M | $550.3M | ||
| Q2 25 | $156.3M | $528.5M | ||
| Q1 25 | $164.2M | $507.7M | ||
| Q4 24 | $228.5M | $511.7M | ||
| Q3 24 | $237.1M | $491.0M | ||
| Q2 24 | $264.3M | $463.2M | ||
| Q1 24 | $266.7M | $378.9M |
总资产APLSCNS
| Q4 25 | $1.1B | $876.7M | ||
| Q3 25 | $1.1B | $801.6M | ||
| Q2 25 | $821.4M | $751.0M | ||
| Q1 25 | $807.3M | $834.9M | ||
| Q4 24 | $885.1M | $812.4M | ||
| Q3 24 | $901.9M | $727.8M | ||
| Q2 24 | $904.5M | $784.1M | ||
| Q1 24 | $831.9M | $680.7M |
负债/权益比APLSCNS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-120.4M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-126.4M |
| 自由现金流率自由现金流/营收 | -7.1% | -87.9% |
| 资本支出强度资本支出/营收 | 0.1% | 4.2% |
| 现金转化率经营现金流/净利润 | — | -3.45× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-253.6M |
8季度趋势，按日历期对齐
经营现金流APLSCNS
| Q4 25 | $-14.2M | $-120.4M | ||
| Q3 25 | $108.5M | $55.1M | ||
| Q2 25 | $4.4M | $-67.6M | ||
| Q1 25 | $-53.4M | $-108.9M | ||
| Q4 24 | $19.4M | $96.7M | ||
| Q3 24 | $34.1M | $25.6M | ||
| Q2 24 | $-8.3M | $31.4M | ||
| Q1 24 | $-133.0M | $4.9M |
自由现金流APLSCNS
| Q4 25 | $-14.3M | $-126.4M | ||
| Q3 25 | $108.3M | $52.6M | ||
| Q2 25 | $4.4M | $-69.8M | ||
| Q1 25 | $-53.4M | $-110.0M | ||
| Q4 24 | $19.3M | $85.0M | ||
| Q3 24 | — | $24.2M | ||
| Q2 24 | $-8.4M | $27.1M | ||
| Q1 24 | $-133.3M | $537.0K |
自由现金流率APLSCNS
| Q4 25 | -7.1% | -87.9% | ||
| Q3 25 | 23.6% | 37.1% | ||
| Q2 25 | 2.5% | -51.3% | ||
| Q1 25 | -32.0% | -81.8% | ||
| Q4 24 | 9.1% | 60.8% | ||
| Q3 24 | — | 18.2% | ||
| Q2 24 | -4.2% | 22.3% | ||
| Q1 24 | -77.3% | 0.4% |
资本支出强度APLSCNS
| Q4 25 | 0.1% | 4.2% | ||
| Q3 25 | 0.0% | 1.8% | ||
| Q2 25 | 0.0% | 1.6% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | 0.0% | 8.3% | ||
| Q3 24 | 0.0% | 1.1% | ||
| Q2 24 | 0.0% | 3.5% | ||
| Q1 24 | 0.2% | 3.5% |
现金转化率APLSCNS
| Q4 25 | — | -3.45× | ||
| Q3 25 | 0.50× | 1.32× | ||
| Q2 25 | — | -1.84× | ||
| Q1 25 | — | -2.74× | ||
| Q4 24 | — | 2.11× | ||
| Q3 24 | — | 0.65× | ||
| Q2 24 | — | 0.99× | ||
| Q1 24 | — | 0.14× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CNS
暂无分部数据
